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OBJECTIVE—A lower in vivo mitochondrial function has been
reported in both type 2 diabetic patients and ﬁrst-degree relatives
of type 2 diabetic patients. The nature of this reduction is
unknown. Here, we tested the hypothesis that a lower intrinsic
mitochondrial respiratory capacity may underlie lower in vivo
mitochondrial function observed in diabetic patients.
RESEARCH DESIGN AND METHODS—Ten overweight dia-
betic patients, 12 ﬁrst-degree relatives, and 16 control subjects,
all men, matched for age and BMI, participated in this study.
Insulin sensitivity was measured with a hyperinsulinemic-eugly-
cemic clamp. Ex vivo intrinsic mitochondrial respiratory capac-
ity was determined in permeabilized skinned muscle ﬁbers using
high-resolution respirometry and normalized for mitochondrial
content. In vivo mitochondrial function was determined by
measuring phosphocreatine recovery half-time after exercise
using
31P-magnetic resonance spectroscopy.
RESULTS—Insulin-stimulated glucose disposal was lower in
diabetic patients compared with control subjects (11.2  2.8 vs.
28.9  3.7 mol  kg
1 fat-free mass  min
1, respectively; P 
0.003), with intermediate values for ﬁrst-degree relatives (22.1 
3.4 mol  kg
1 fat-free mass  min
1). In vivo mitochondrial
function was 25% lower in diabetic patients (P  0.034) and 23%
lower in ﬁrst-degree relatives, but the latter did not reach
statistical signiﬁcance (P  0.08). Interestingly, ADP-stimulated
basal respiration was 35% lower in diabetic patients (P  0.031),
and ﬂuoro-carbonyl cyanide phenylhydrazone–driven maximal
mitochondrial respiratory capacity was 31% lower in diabetic
patients (P  0.05) compared with control subjects with inter-
mediate values for ﬁrst-degree relatives.
CONCLUSIONS—A reduced basal ADP-stimulated and maxi-
mal mitochondrial respiratory capacity underlies the reduction in
in vivo mitochondrial function, independent of mitochondrial
content. A reduced capacity at both the level of the electron
transport chain and phosphorylation system underlies this im-
paired mitochondrial capacity. Diabetes 57:2943–2949, 2008
S
keletal muscle insulin resistance is one of the
earliest hallmarks in the development of type 2
diabetes. In recent years, mitochondrial dysfunc-
tion has been suggested to underlie the develop-
ment of insulin resistance and type 2 diabetes (1–5). An
impaired mitochondrial function may contribute to in-
creased lipid accumulation in skeletal muscle (intramyo-
cellular lipid [IMCL] content) but also in heart and liver.
Lipid intermediates are thought to interfere with the
insulin signaling pathway (2). Petersen et al. (3) were the
ﬁrst to report that mitochondrial dysfunction may be a
factor in the etiology of insulin resistance. Using noninva-
sive phosphorus magnetic resonance spectroscopy (
31P-
MRS), they applied a magnetization saturation transfer
method to calculate unidirectional ATP synthesis rate.
Using this methodology, they reported that resting muscu-
lar ATP synthesis was decreased by 40% in insulin-
resistant elderly compared with insulin-sensitive young
control subjects (3). Similar results were obtained when
lean but insulin-resistant offspring of type 2 diabetic
patients were compared with insulin-sensitive healthy
subjects matched for age, BMI, and habitual physical
activity (6). The offspring of type 2 diabetic patients were
characterized by an 60% lower rate of muscular glucose
uptake and 30% lower rates of resting muscular ATP
synthesis rate. A decreased mitochondrial function in
diabetes-prone subjects like ﬁrst-degree relatives of type 2
diabetic patients suggests that mitochondrial defects may
underlie the pathogenesis of diabetes. Recently, the
observations of compromised mitochondrial function in
diabetes-prone subjects reﬂected as reduced ATP syn-
thesis has been extended to nonobese, metabolically
well-controlled type 2 diabetic patients (7). However,
when this population of type 2 diabetic patients was
matched to age-matched control subjects, no differ-
ences in ATP synthesis rate were found. In contrast,
using an alternative method to measure in vivo mito-
chondrial function with
31P-MRS, we recently showed
an 40% lower mitochondrial function in type 2 diabetic
patients compared with age- and BMI-matched control
subjects (8). With this method, phosphocreatine (PCr)
kinetics are evaluated during recovery from submaximal
exercise (9,10). During exercise, PCr content decreases
to reach a steady state and recovers rapidly after
exercise. This PCr resynthesis is driven almost purely
oxidatively (11). Therefore, the rate of PCr resynthesis
(e.g., the half-time of recovery) reﬂects in vivo mito-
chondrial oxidative capacity or function (12). A pro-
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patients (8), therefore indicates decreased mitochon-
drial function. Both
31P-MRS methods give important
information on mitochondrial function, but it should be
noted that the two methods should be interpreted
differently: the PCr recovery method determines the
maximal capacity of the oxidative system, whereas the
ATP-saturation transfer method measures the momentary
ﬂux of ATP synthesis in the resting state. Taken together,
studies examining in vivo mitochondrial function using
31P-MRS point toward diminished mitochondrial function
related to type 2 diabetes, although results may vary
depending on age and BMI of the control groups.
Why in vivo mitochondrial function is reduced cannot
be deduced from
31P-MRS. In fact, a lower in vivo mito-
chondrial “function” can be the result of several factors,
including a reduced mitochondrial density, lower muscle
perfusion, but also a true mitochondrial dysfunction (i.e.,
lower mitochondrial respiratory capacity per mitochon-
drion). To examine the causes of lower in vivo mitochon-
drial function, ex vivo determination of mitochondrial
function is of particular interest because it allows studying
intrinsic mitochondrial capacity under a variety of sub-
strates. So far, three studies have reported mitochondrial
function ex vivo in a diabetic population (13–15), with
conﬂicting results. These studies did not determine in vivo
mitochondrial function and can therefore not answer the
question whether a reduced in vivo mitochondrial func-
tion, as has repeatedly been observed in type 2 diabetic
patients, can be attributed to a reduced intrinsic mitochon-
drial respiratory capacity.
Therefore, the aim of the present study was to identify
the underlying defects of impaired in vivo mitochondrial
function in a comparable diabetic population as in which
we previously showed reduced in vivo mitochondrial
function. To this end, detailed ex vivo mitochondrial
respirometry was combined within the same subject with
in vivo mitochondrial function in patients with type 2
diabetes, and results were compared with ﬁrst-degree
relatives and with age- and BMI-matched control subjects.
RESEARCH DESIGN AND METHODS
Ten male type 2 diabetic patients (diabetic patients), 12 male ﬁrst-degree
relatives, and 16 male control subjects (Table 1) were included in this study,
which was approved by the institutional medical ethical committee. Subjects
were recruited via advertisement in local papers and gave their written
informed consent. Before the onset of the study, a medical history and
physical examination was performed, and a resting electrocardiogram was
taken. Subjects with uncontrolled hypertension, active cardiovascular dis-
ease, or liver dysfunction or subjects on medication known to interfere with
glucose metabolism (except for diabetic patients) were excluded from par-
ticipation. Control subjects and ﬁrst-degree relatives underwent a 2-h oral
glucose tolerance test according to World Health Organization criteria.
Diabetic patients were diagnosed with type 2 diabetes at least 2 years before
the start of the study and had well-controlled diabetes (A1C 7.1  0.2). All
diabetic patients were on metformin, and three patients were on sulfonylurea
in combination with metformin. Furthermore, none of the diabetic patients
followed a prescribed dietary program. Control subjects had no family history
of type 2 diabetes; whereas ﬁve ﬁrst-degree relatives had one ﬁrst-line family
member (father, mother, brother, or sister) diagnosed with type 2 diabetes,
and seven were multiple relatives. All ﬁrst-degree relatives were not related to
the diabetic patients included in this study. All subjects performed a maximal
aerobic capacity test as described previously (16). Body composition was
determined using hydrostatic weighing (17).
To measure peripheral insulin sensitivity, a 3-h hyperinsulinemic-euglyce-
mic (40 mU  m
2  min
1) clamp, according to DeFronzo (18), was performed
after an overnight fast with primed infusion of [6,6-
2H2]glucose (0.04 mg  kg
1
 min
1) to determine rates of glucose appearance (Ra) and disposal (Rd), as
previously described (19). One week before the hyperinsulinemic-euglycemic
clamp, patients were withdrawn from their antidiabetic medication. Basal and
insulin-stimulated measurements were performed, including blood sampling
and indirect calorimetry. Type 2 diabetic patients were clamped at higher
glucose values than ﬁrst-degree relatives and control subjects (6.2  0.2, 5.7 
0.1, and 5.7  0.1, respectively, P  0.05) because of their hyperglycemia at the
onset of the clamping procedure. Muscle biopsies were taken before the
clamp, under local anesthesia (2% lidocaïne), according to the technique of
Bergstro ¨m et al. (20).
On a separate day, at least 1 week before the clamp or after the clamp,
subjects performed a knee-extension exercise protocol on a home-built
magnetic resonance compatible ergometer with a pulley system in a 1.5-T
whole-body scanner (Intera; Philips Medical Systems, Best, the Netherlands),
and PCr kinetics were analyzed after exercise, as described previously (8).
Exercise was performed for 5 min with a weight corresponding to 60% of
maximal capacity, which was determined with an incremental maximal test
with the same ergometer on a different day. Low- to medium-intensity exercise
was chosen to prevent acidiﬁcation, which is known to affect PCr recovery.
Subjects consumed an early lunch 2 h before the PCr kinetics test. On the
same day,
1H-MRS imaging was performed in the m. vastus lateralis to analyze
IMCL content, as described in detail previously (8). IMCL content is reported
as the percentage of the signal intensity of the CH2 peak of IMCL, compared
with the intensity of the water resonance. One diabetic patient, two ﬁrst-
degree relatives, and four control subjects were excluded for in vivo
31P-MRS
and
1H-MRS imaging for medical reasons, including metal orthopedic im-
plants, severe claustrophobia, or technical problems.
Isolation and permeabilization of muscle ﬁbers. A small portion (30
mg) was immediately placed in ice-cold biopsy containing preservation
medium (BIOPS; OROBOROS Instruments, Innsbruck, Austria). Muscle ﬁbers
were permeabilized with saponin according to the technique of Veksler et al.
(21). After completion of the permeabilization protocol, muscle ﬁbers were
transferred into ice-cold mitochondrial respiration buffer (MiRO5; OROBO-
ROS Instruments). Subsequently, the muscle ﬁbers were transferred to the
oxygraph to perform high-resolution respirometry corrected for wet weight.
High-resolution respirometry. Mitochondrial function ex vivo was quanti-
ﬁed by measuring oxygen consumption polarographically using a two-cham-
ber Oxygraph (OROBOROS Instruments). Oxygen consumption reﬂects the
ﬁrst derivative of the oxygen concentration (nmol/ml) in time in the respira-
tion chambers and is termed oxygen ﬂux [pmol/(s*mg)], corrected for wet
weight muscle tissue (2–5 mg) introduced into the chamber. To evaluate
oxidative phosphorylation, different substrate inhibition protocols were used.
In every protocol applied, ﬁrst, 4.0 mmol/l malate was added to obtain state 2
respiration followed by addition of 8.0 mmol/l glutamate as a substrate for
complex I with or without 40.0 mol/l palmitoyl-carnitine. In addition, an
excess of 1.6 mmol/l ADP was added to evaluate state 3 respiration of complex
I. Then 8.0 mmol/l succinate was added to obtain state 3 respiration by
activating both complex I and II. Finally, 1.6 g/ml oligomycin or titrations of
the uncoupler 1.0 mmol/l ﬂuoro-carbonyl cyanide phenylhydrazone (FCCP)
were added to evaluate state 4 respiration or maximal respiratory capacity,
state u, respectively.
Measures of mitochondrial density. For citrate synthase activity, 10 mg m.
vastus lateralis muscle biopsy was cut with a cryostat (20°C), dissolved in
100 l cold SET buffer (containing 250 mmol/l sucrose, 2 mmol/l EDTA, and
10 mmol/l Tris-HCl, adjusted pH at 7.4), and processed for spectrophotometric
analysis of citrate synthase activity according to Shephard and Garland (22).
Mitochondrial DNA (mtDNA) copy number was determined as a marker for
mitochondrial density using quantitative real-time PCR, based on the TaqMan
probe method. TaqMan primers and probes are shown in Table 2. mtDNA copy
TABLE 1
Subject characteristics
Control
subjects
First-degree
relatives
Diabetic
patients
Age (years) 59.2  0.7 60.1  0.9 61.4  1.6
Body weight (kg) 92.3  2.6 91.6  3.8 89.2  3.3
BMI (kg/m
2) 29.1  0.7 30.1  1.2 28.9  0.7
Fat (%) 31.4  1.7 29.4  1.9 27.9  2.3
Fat-free mass (kg) 62.8  1.9 62.5  3.2 63.7  2.0
Vo2max (ml  kg
1 
min
1) 31.2  1.6 32.6  9.6 28.2  2.3
Glucose (mmol/l) 6.0  0.2 6.0  0.2 8.6  0.6*†
Insulin (mU/l) 13.7  2.1 14.5  1.8 17.5  2.1
NEFA (mol/l) 464  22 432  41 526  49
Data are means  SE. *P  0.05 diabetic patients vs. control
subjects; †P  0.05 diabetic patients vs. ﬁrst-degree relatives.
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(ND1) to lipoprotein lipase (LPL) (mtDNA/nuclear DNA), as described previ-
ously (23).
Plasma assays. Blood collected in tubes containing EDTA was immediately
centrifuged at high speed, and plasma was frozen in liquid nitrogen and stored
at 80°C until assayed. Plasma nonesteriﬁed fatty acids (NEFAs) and glucose
were measured with enzymatic assays automated on a Cobas Fara/Mira
(NEFA: Wako Nefa C test kit; Wako Chemicals, Neuss, Germany) (glucose:
hexokinase method; LaRoche, Basel, Switzerland). Insulin concentration was
determined using a radioimmunoassay (Linco Reseach, St. Charles, MO).
Isotopic enrichment of plasma glucose was determined by electron ionization
gas chromatography–mass spectrometry and expressed as tracer-to-tracee
ratio.
Calculations. Steele’s single-pool non–steady-state equations were used to
calculate glucose Ra and Rd (24). Volume of distribution was assumed to be
0.160 l/kg for glucose. Endogenous glucose production (EGP) was calculated
as Ra minus exogenous glucose infusion rate. Both in the basal state and
during insulin stimulation, substrate oxidation was measured by indirect
calorimetry. Fat and carbohydrate oxidation were calculated using stoichio-
metric equations according to Frayn (25) with the assumption that protein
oxidation was negligible. Nonoxidative glucose disposal was calculated as Rd
minus carbohydrate oxidation. Metabolic ﬂexibility was expressed as the
change in respiratory quotient from the fasted state to the insulin-stimulated
condition.
Statistics. Data are reported as means  SE. Statistical analyses were
performed using the statistical computer program SPSS 11.0.4 for Mac OS X.
Differences between groups were analyzed by one-way ANOVA with a Tukey’s
honestly signiﬁcant difference post hoc correction. We computed Spearman
correlation coefﬁcients to correlate parameter values. Differences were con-
sidered signiﬁcant when P  0.05.
RESULTS
Subjects. All groups were carefully matched for age and
BMI (age 61.4  1.6, 60.1  0.9, and 59.2  0.7 years; BMI
28.9  0.7, 30.1  1.2, and 29.1  0.7 kg/m
2, respectively,
for diabetic patients, ﬁrst-degree relatives, and control
subjects) (Table 1). Maximal aerobic capacity (Vo2max)
was not different between groups (Vo2max 28.2  2.3,
32.6  9.6, and 31.2  1.6 ml  kg
1  min
1, respectively,
in diabetic patients, ﬁrst-degree relatives, and control
subjects) (Table 1). By deﬁnition, fasting plasma glucose
concentration was signiﬁcantly higher in diabetic patients
compared with ﬁrst-degree relatives and control subjects
(Table 1). Fasting plasma insulin and NEFA concentra-
tions were not different between groups (Table 1).
Insulin-mediated glucose uptake. Basal glucose uptake
(Rd) was signiﬁcantly higher in diabetic patients compared
with control subjects (Table 3; P  0.024). Insulin-stimu-
lated glucose disposal, expressed as Rd during insulin
infusion minus basal Rd, was signiﬁcantly decreased in
diabetic patients compared with control subjects (Table 3;
P  0.003). First-degree relatives had intermediate values
for basal Rd and insulin-stimulated glucose disposal; how-
ever, these values were not different from control subjects
or diabetic patients. A reduced insulin-stimulated glucose
oxidation (P  0.05) and nonoxidative glucose uptake
(P  0.03) accounted for the lower insulin-stimulated
glucose disposal in diabetic patients (Table 3). Also, for
these parameters, values reported for ﬁrst-degree relatives
were in between control subjects and diabetic patients.
Basal EGP, reﬂecting hepatic glucose output, was higher
in diabetic patients compared with control subjects (Table
3; P  0.028), with intermediate values for ﬁrst-degree
relatives. EGP was almost completely suppressed during
TABLE 2
Primers/probes used in quantitative RT-PCR for quantiﬁcation of mtDNA copy number
Gene Forward primer Probe Reverse primer
ND1 CCC TAA AAC CCG CCA CAT CT CCA TCA CCC TCT ACA TCA
CCG CCC
GAG CGA TGG TGA GAG CTA AGG T
LPL CGA GTC GTC TTT CTC CTG ATG AT ACA TTC ACC AGA GGG TC TTC TGG ATT CCA ATG CTT CGA
TABLE 3
Substrate kinetics
Control
subjects
First-degree
relatives
Diabetic
patients
Rd glucose (mol  kg
1 fat-free mass  min
1)
Basal 12.1  1.0 14.2  1.8 17.3  1.3*
Clamp 41.0  3.7 36.2  3.5 28.4  2.7*
Change (Rd clamp–Rd basal) 28.9  3.7 22.1  3.4 11.2  2.8*
EGP (mol  kg
1 fat-free mass  min
1)
Basal 11.9  1.0 11.7  1.4 16.3  1.1*
Clamp 2.0  1.2 2.4  1.2 4.1  1.5
Change (EGP basal–EGP clamp) 9.8  1.5 9.3  0.9 12.2  1.5
Carbohydrate oxidation (mol  kg
1 fat-free mass  min
1)
Basal 8.9  0.5 11.6  1.9 10.6  0.9
Clamp 20.6  2.3 19.6  1.3 15.3  0.6
Change (CHO ox clamp–CHO ox basal) 11.7  2.5 8.1  1.5 4.6  0.8*
NOGD (mol  kg
1 fat-free mass  min
1)
Basal 2.9  1.3 2.7  2.2 6.6  1.6
Clamp 22.6  3.3 16.4  3.3 13.2  2.9
Change (NOGD clamp–NOGD basal) 19.7  3.7 13.7  3.7 6.5  2.6*
Lipid oxidation (mol  kg
1 fat-free mass  min
1)
Basal 5.1  0.3 4.8  0.4 4.9  0.2
Clamp 3.0  0.3 2.8  0.4 3.8  0.2
Change (lipid ox basal–lipid ox clamp) 2.3  0.3 2.0  0.3 1.1  0.2*
Data are means  SE. NOGD, nonoxidative glucose disposal. *P  0.05 between diabetic patients and control subjects. CHOox, carbohydrate
oxidation.
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had signiﬁcantly lower insulin-suppressed lipid oxidation
values compared with control subjects (Table 3; P 
0.028).
Metabolic ﬂexibility. Metabolic ﬂexibility, i.e., the in-
crease in respiratory quotient (RQ) from basal to insulin
stimulation, was signiﬁcantly lower in diabetic patients
compared with control subjects (0.04  0.01 vs. 0.09 
0.01, respectively; P  0.014). First-degree relatives did not
signiﬁcantly differ from control subjects or diabetic pa-
tients (Fig. 1).
Intramyocellular lipid content. No differences were
found for IMCL content between groups (1.0  0.2, 0.9 
0.1, and 0.8  0.1%, respectively, for diabetic patients,
ﬁrst-degree relatives, and control subjects).
In vivo mitochondrial function. Mean PCr recovery
half-time (PCr-t1/2) was prolonged by 25% in diabetic
patients compared with control subjects (23.8  2.0 vs.
17.9  1.2 s, respectively; P  0.034) (Fig. 2), indicating
impaired in vivo mitochondrial function in diabetic pa-
tients. First-degree relatives had a 23% longer PCr-t1/2
compared with control subjects (23.1  2.0 s vs. 17.9 
1.2 s; Fig. 2), however, this did not reach statistical
signiﬁcance (P  0.08). PCr levels decreased during knee-
extension exercise until a steady state was reached. None
of the subjects showed acidiﬁcation at the end of the
exercise protocol, and the pH decreased similarly from
rest to end-exercise in all groups (end-exercise pH 7.02 
0.02, 7.01  0.03, and 7.05  0.03; pH 0.08  0.02, 0.08 
0.03, and 0.07  0.03, respectively, in diabetic patients,
ﬁrst-degree relatives, and control subjects).
Mitochondrial density. Mitochondrial density measured
as mtDNA copy number and as citrate synthase activity
was not different between groups (mtDNA copy number
5,813  388, 5,573  716, and 5,621  430 arbitrary units;
citrate synthase activity 92  4.8, 103  13.0, and 89  7.4
mol  g
1 protein  min
1, respectively, in diabetic pa-
tients, ﬁrst-degree relatives, and control subjects; NS).
Ex vivo mitochondrial function. Unnormalized basal
ADP-stimulated state 3 respiration was signiﬁcantly lower
in diabetic patients compared with control subjects
[20.1  1.0 vs. 27.0  1.8 pmol/(s*mg), respectively; P 
0.024]. First-degree relatives did not signiﬁcantly differ
from control subjects or diabetic patients [24.9  2.1
pmol/(s*mg)]. No difference in respiration was found
between groups when ATP synthase was blocked with
oligomycin (non-ADP–stimulated state 4 respiration)
[12.1  0.9, 11.0  0.9, and 11.7  0.8 pmol/(s*mg),
respectively, for diabetic patients, ﬁrst-degree relatives,
and control subjects]. Although maximal respiratory ca-
pacity (FCCP-driven state u) was lower in diabetic pa-
tients compared with control subjects, differences
between groups did not reach statistical signiﬁcance
[40.5  3.3, 45.1  5.3, and 51.9  4.3 pmol/(s*mg),
respectively, for diabetic patients, ﬁrst-degree relatives,
and control subjects]. When palmitoyl-carnitine was added
as a substrate, similar tendencies were found (data not
shown). To obtain intrinsic mitochondrial function, all O2
ﬂuxes were normalized for mtDNA copy numbers, a
marker for mitochondrial density, expressed as pmol/
(s*mg)/mtDNA copy numbers  10.000 (Table 4). Similar
results were obtained when ex vivo data were normalized
for citrate synthase activity (data not shown). After nor-
malization, state 3 respiration was lower by 35% in diabetic
patients compared with control subjects (P  0.031; Table
4; Fig. 3A). Values in ﬁrst-degree relatives were not signif-
icantly different from control subjects or diabetic patients
(46.1  4.8; Table 4; Fig. 3A). State 4 respiration was not
different between groups (Table 4). Maximal respiratory
capacity (FCCP-driven state u) after normalization was
signiﬁcantly lower in diabetic patients compared with
control subjects (P  0.05; Table 4; Fig. 3B) and tended to
be lower in ﬁrst-degree relatives compared with control
subjects (P  0.10; Table 4; Fig. 3B). When palmitoyl-
carnitine was added as a substrate, similar tendencies
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FIG. 1. Metabolic ﬂexibility, measured as the change in respiratory
quotient from the fasted state to the insulin-stimulated condition, in
control subjects, ﬁrst-degree relatives, and diabetic patients. , con-
trol; p, FDR; f, type 2 diabetic patients. *P < 0.05 compared with
diabetic patients.
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FIG. 2. In vivo mitochondrial function expressed as PCr half-time (s) in
control subjects, ﬁrst-degree relatives, and diabetic patients. , con-
trol; p, FDR; f, type 2 diabetic patients. *P < 0.05 compared with
diabetic patients.
TABLE 4
Normalized ex vivo mitochondrial respiration
Control
subjects
First-
degree
relatives
Diabetic
patients
State 3 on malate 	
glutamate 	
succinate 53.8  5.7 46.1  4.8 35.1  1.7*
State 4 23.0  2.1 20.1  2.0 20.8  1.6
State u 105.8  9.5 77.5  11.4 72.8  6.9*
State 3 on malate 	
palmitoyl-carnitine 	
glutamate 	
succinate 60.8  6.9 55.5  4.6 42.1  2.8
State 4 34.4  2.8 32.2  4.3 28.6  2.0
State u 113.8  14.4 80.2  6.4 88.8  9.9
Data are means  SE and are pmol/(s*mg)/(mtDNA copy numbers 
10,000). *P  0.05 diabetic patients vs. control subjects.
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carnitine plus glutamate plus succinate addition) tended to
be lower in diabetic patients compared with control
subjects with no difference in ﬁrst-degree relatives (Table
4). No differences were found between diabetic patients,
ﬁrst-degree relatives, and control subjects for state 4
respiration on addition of palmitoyl-carnitine (Table 4).
Maximal respiratory capacity in the presence of palmitoyl-
carnitine tended to be lower in ﬁrst-degree relatives com-
pared with control subjects (P  0.1; Table 4). The value in
diabetic patients was not signiﬁcantly different (Table 4).
Correlations. A strong correlation was found between in
vivo mitochondrial function (i.e., PCr-t1/2) and Vo2max
(correlation coefﬁcient 0.597, P  0.000). Also, in vivo
mitochondrial function correlated with mtDNA copy num-
bers (correlation coefﬁcient 0.477, P  0.007). Further-
more, in vivo mitochondrial function correlated with
insulin-stimulated glucose oxidation (correlation coefﬁ-
cient 0.424, P  0.020). Unnormalized state 3 respiration
(on malate plus glutamate plus succinate addition) corre-
lated negatively with fasting glucose (correlation coefﬁ-
cient 0.408, P  0.016) and with in vivo mitochondrial
function (PCr-t1/2) (correlation coefﬁcient 0.373, P 
0.05). Metabolic ﬂexibility expressed as RQ correlated
with unnormalized state 3 respiration (on addition of
malate plus glutamate plus palmitoyl-carnitine plus succi-
nate) (correlation coefﬁcient 0.338, P  0.047) and with in
vivo mitochondrial function (PCr-t1/2) (correlation coefﬁ-
cient 0.368, P  0.042). No correlations were found for in
vivo or ex vivo mitochondrial function with insulin-stimu-
lated Rd or with IMCL and/or free fatty acid levels.
DISCUSSION
Mitochondrial dysfunction has recently been implicated in
the etiology of insulin resistance and type 2 diabetes. This
suggestion is mainly based on studies that determined in
vivo mitochondrial function (6–8). However, it is not yet
elucidated whether intrinsic mitochondrial defects cause
this lower in vivo mitochondrial function in type 2 diabetic
patients and ﬁrst-degree relatives. Ex vivo studies on
mitochondrial function in type 2 diabetic patients appear
less conclusive (13–15); however, in these studies, in vivo
mitochondrial function was not assessed. To identify the
true nature of reduced mitochondrial function in type 2
diabetic patients, the combination of in vivo and ex vivo
measurements are of importance. Thus, impaired in vivo
mitochondrial function might be caused by an impaired
intrinsic capacity per mitochondrion or lower mitochon-
drial content. In this study, we performed both in vivo and
ex vivo measurement of mitochondrial function in male
diabetic patients, ﬁrst-degree relatives, and control sub-
jects, all matched for age and BMI.
We conﬁrmed our previous ﬁnding (8) of compro-
mised in vivo mitochondrial function, determined as the
rate of PCr recovery after exercise in type 2 diabetic
patients compared with age- and BMI-matched control
subjects, and we extend these ﬁndings to a tendency to
reduced in vivo mitochondrial function in normoglyce-
mic ﬁrst-degree relatives. In fact, this reduction in in
vivo mitochondrial function was more pronounced in
the seven subjects with multiple type 2 diabetic relatives
(data not shown). Lower basal ATP synthesis rate in
insulin-resistant ﬁrst-degree relatives has been reported
previously (6) when compared with insulin-sensitive
healthy control subjects. Here, we report tendency to
compromised mitochondrial function in ﬁrst-degree rel-
atives who possessed (nonsigniﬁcant) intermediate val-
ues of insulin sensitivity (the Rd of glucose, EGP, and
nonoxidative glucose disposal) compared with age- and
BMI-matched control subjects. This may suggest that a
compromised mitochondrial function is an early defect
in the pathogenesis of type 2 diabetes.
Interestingly, using high-resolution respirometry in per-
meabilized skinned muscle ﬁbers, we identiﬁed lower
ADP-driven state 3 respiration as an intrinsic mitochon-
drial defect (ex vivo) that underlies the mitochondrial
dysfunction observed in vivo. However, mitochondrial
dysfunction was not related to insulin sensitivity or IMCL
content, and the latter was not different between groups.
This is in line with earlier ﬁndings, in which no differences
in IMCL were found between BMI-matched overweight
diabetic patients and control subjects (8). Most likely, the
combination of low oxidative capacity and fat content in
muscle will lead to the accumulation of fatty acid inter-
mediates, leading to muscular insulin resistance. Interest-
ingly, the compromised ex vivo mitochondrial function
could not be attributed to the mitochondrial density
because the differences across groups remained on nor-
malization to mtDNA copy number or citrate synthase.
Moreover, even if in vivo mitochondrial function was
adjusted for mtDNA copy number, differences between
groups remained similar, as could be deduced from the
similarity in mtDNA copy number between groups (data
not shown). Thus, here, we show intrinsic mitochondrial
defects in type 2 diabetic patients and similar tendencies
in diabetes-prone ﬁrst-degree relatives, which may under-
lie the mitochondrial dysfunction found in vivo.
FIG. 3. Ex vivo state 3 (A) and state u respiration (B) normalized for
mitochondrial content expressed as pmol  (s  mg)
1  mtDNA copy
number
1 (10.000) in control subjects, ﬁrst-degree relatives, and
diabetic patients. , control; p, FDR; f, type 2 diabetic patients. *P <
0.05 compared with diabetic patients.
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ﬁnding that intrinsic mitochondrial function, if also nor-
malized to mitochondrial content, is lower in type 2
diabetic patients, and tended to be lower in ﬁrst-degree
relatives. Thus, both ADP-stimulated state 3 respiration
and FCCP-driven maximal state u respiration were signif-
icantly lower (30%) in diabetic patients compared with
control subjects. ADP-stimulated state 3 respiration re-
ﬂects the capacity of the mitochondria to reduce the
tricarboxylic acid cycle and 
-oxidation–derived reducing
equivalents NADH and FADH2 in the electron transport
chain (ETC), resulting in oxidative phosphorylation of
ADP to synthesize ATP at the level of ATP synthase. Under
physiological conditions, the rate of state 3 respiration is
limited by, or under control of, the activity of the phos-
phorylation system (including ATP synthase and ANT).
Thus, bypassing the phosphorylation system ex vivo by the
use of the chemical uncoupler FCCP results in a stimula-
tion of respiration, called state u respiration. State u
respiration hence reﬂects the maximal capacity of the ETC
and the upstream dehydrogenases (malate, glutamate, and
succinate dehydrogenase) involved in hydrolysis of the
substrates supplied. This can therefore be referred to as
maximal, uncontrolled mitochondrial oxidative capacity.
The reduction of 30% in state u respiration as observed
in type 2 diabetic patients therefore indicates a reduced
maximal mitochondrial oxidative capacity in these pa-
tients that may reside at the level of the ETC and the
upstream dehydrogenases. However, we found that state 3
respiration was also affected to a similar extent. Although,
this could theoretically be explained by the reduced
maximal mitochondrial capacity mentioned above (and
thus at the level of the ETC and/or dehydrogenases), it
should be noted that respiration was still stimulated on
FCCP addition, in fact to a similar extent in type 2 diabetic
patients and control subjects. Thus, state u respiration
(ETC activity and upstream dehydrogenases) exceeds the
level of state 3 respiration in all groups, indicating that also
in type 2 diabetic patients, state 3 respiration is being
limited by the phosphorylation system. Therefore, the 30%
reduction in state 3 in diabetic patients indicates that the
capacity of the phosphorylation systems is also reduced in
these patients. Therefore, taken together, these data point
toward a reduced intrinsic mitochondrial defect that re-
sides both at the level of the ETC activity and/or upstream
dehydrogenases and at the level of the phosphorylation
system.
In ﬁrst-degree relatives, the tendency to a lower in vivo
mitochondrial function was accompanied by a tendency to
a lower maximal respiratory capacity (state u), but no
defect in state 3 respiration. A lower state u respiration,
with unaffected state 3 respiration, points toward a re-
duced maximal ETC activity, without a reduction in the
phosphorylation system. Thus, a tendency toward lower
state u respiration in ﬁrst-degree relatives suggests that
mitochondria of ﬁrst-degree relatives are capable of com-
pensating the reduced maximal mitochondrial capacity by
respiring on a higher percentage of the ETC capacity, i.e.,
with less tight control by the phosphorylation system.
Mitochondrial entrance of fatty acids via the carnitine
shuttle system is classically believed to be rate limiting for

-oxidation. Using palmitoyl-carnitine, this putative limi-
tation in fat oxidation is circumvented, thereby maximiz-
ing the ﬂow through the 
-oxidation. Through the addition
of palmitoyl-carnitine to the substrate cocktail, additional
reducing equivalents not requiring malate, glutamate, or
succinate dehydrogenases are fed into the ETC. The
addition of palmitoyl-carnitine, however, did not rescue
the defects detected when using malate, glutamate, or
succinate as substrates. This is an important observation
suggesting that the defects observed in type 2 diabetic
patients are unlikely to be localized in the malate, gluta-
mate, and succinate dehydrogenases but are more likely to
be located at the level of the ETC and the phosphorylation
system. This indicates a lower overall intrinsic mitochon-
drial oxidative capacity. The reason for the latter is
unknown but may involve ultrastructural mitochondrial
changes. In that respect, smaller mitochondria have been
reported for type 2 diabetic patients (1), and mitochon-
drial size was related to insulin sensitivity (1,26). Whether
mitochondrial size determines overall mitochondrial ca-
pacity in these patients needs further investigation.
A putatively confounding factor when studying mito-
chondrial function is the level of physical activity of the
subjects. In our study, we included sedentary subjects and
type 2 diabetic patients without comorbidities. All subjects
ﬁlled out a physical activity questionnaire indicating low
levels of physical activity without differences between
groups. Also maximal aerobic performance, which is a
reﬂection of physical ﬁtness, was similar between groups.
This suggests that in the present study, the lower mito-
chondrial function in type 2 diabetes and tendency in
ﬁrst-degree relatives was not due to differences in level of
habitual physical activity. Because physical activity is the
major driver of mitochondrial biogenesis (27), the low and
comparable level of physical activity may also explain why
we did not observe any differences in mitochondrial
content (determined by citrate synthase activity and
mtDNA copy number) among diabetic patients, ﬁrst-de-
gree relatives, and control subjects.
Mitochondrial dysfunction implicated in type 2 diabetes,
as shown in the present study, may alter substrate oxida-
tion and might underlie the blunted increase in fat oxida-
tion under conditions such as fasting, despite the presence
of high circulating plasma levels of NEFA (28). This defect
has been termed “metabolic inﬂexibility” and can also be
observed as a reduced response to insulin, i.e., a reduced
enhancement of glucose oxidation during insulin stimula-
tion (29). A previous study indicated a link between
defects in substrate switching and mitochondrial defects
as shown in young, sedentary, healthy ﬁrst-degree rela-
tives (30). In their study, ﬁrst-degree relatives were meta-
bolic inﬂexible after consuming a high-fat diet, suggesting
a decreased ability to enhance fat oxidation. In the present
study, we observed metabolic inﬂexibility in type 2 dia-
betic patients, but not in ﬁrst-degree relatives, together
with a (tendency to) reduced in vivo mitochondrial func-
tion in both type 2 diabetic patients and ﬁrst-degree
relatives. Therefore, our data do not entirely match with
the suggestion that mitochondrial dysfunction underlies
this metabolic inﬂexibility. However, the change in respi-
ratory quotient on insulin stimulation is more likely to be
a reﬂection of reduced skeletal muscle insulin sensitivity.
In conclusion, the present study supports the hypothesis
that intrinsic mitochondrial dysfunction is implicated in
the etiology of type 2 diabetes. In vivo mitochondrial
function was accompanied by lower ADP-driven mito-
chondrial respiration, if corrected for mitochondrial den-
sity. These mitochondrial aberrations are located at the
level of both electron-transport chain capacity and oxida-
tive phosphorylation system. Our data suggest that a
reduced intrinsic ADP-stimulated mitochondrial respira-
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